logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2018 – Global health status, quality of life data favour talazoparib in patients with triple negative breast cancer and BRCA1/2 mutations

Women with triple negative advanced breast cancer and BRCA1/2 mutations in the EMBRACA trial had better QoL on talazoparib vs physician’s choice chemotherapy